drugset / Trial / NCT03373383

Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy

NCT03373383

Phase 2 Completed 411 enrolled UCB Biopharma S.P.R.L.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to characterize the dose-response relationship with respect to efficacy of Padsevonil administered concomitantly with up to 3 anti-epileptic drugs (AEDs) for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy.

Timeline

Start
2018-02-12
Primary completion
2020-01-30
Completion
2020-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Padsevonil Small molecule 50 mg
Subject Padsevonil Small molecule 100 mg
Subject Padsevonil Small molecule 200 mg
Subject Padsevonil Small molecule 400 mg

Indications